Home > Boards > US Listed > Medical - Drugs > Anika Therapeutics Inc. (ANIK)

Anika Therapeutics Announces U.S. Distribution Agreement for Advanced

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 438
Posts 25,354
Boards Moderated 2
Alias Born 09/11/06
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 5/22/2020 4:59:09 PM
Anika to Participate in 2020 UBS Virtual Global Healthcare Conference Business Wire - 5/12/2020 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2020 6:02:08 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 4:08:10 PM
Anika Reports First Quarter 2020 Financial Results GlobeNewswire Inc. - 5/7/2020 4:05:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2020 4:17:07 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/29/2020 4:14:04 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/29/2020 4:07:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/28/2020 6:41:48 PM
Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer Business Wire - 4/27/2020 8:30:00 AM
Anika to Issue First Quarter 2020 Financial Results and Business Highlights on Thursday, May 7 Business Wire - 4/23/2020 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/8/2020 4:06:04 PM
Anika Takes Actions to Strengthen Liquidity in Light of COVID-19 GlobeNewswire Inc. - 4/8/2020 4:05:10 PM
Unknown (sec Staff) Edgar (US Regulatory) - 3/18/2020 10:46:18 AM
Unknown (sec Staff) Edgar (US Regulatory) - 3/18/2020 10:45:38 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 3/13/2020 4:06:09 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 3/13/2020 4:06:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/6/2020 4:11:58 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 3/6/2020 4:06:48 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/6/2020 6:02:04 AM
Anika Appoints David Colleran as General Counsel Business Wire - 3/4/2020 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/2/2020 4:06:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/27/2020 6:55:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/27/2020 6:54:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/27/2020 6:53:52 PM
surf1944   Monday, 07/04/11 11:07:05 AM
Re: surf1944 post# 80
Post # of 111 
Anika Therapeutics Announces U.S. Distribution Agreement for Advanced Wound Care Product

Misonix Named Exclusive Domestic Distributor of Anika’s Hyalomatrix® Skin Substitute

Press Release Source: Anika Therapeutics On Wednesday June 1, 2011, 4:15 pm EDT

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq:ANIK - News), a leader in products for tissue protection, healing, and repair, based on hyaluronic acid (“HA”) technology, today announced Anika Therapeutics S.r.l., its wholly owned subsidiary, has entered into a new, five-year exclusive U.S. distribution agreement with Misonix, Inc. (Nasdaq:MSON - News), which will distribute and sell Anika’s Hyalomatrix®—an FDA-approved, HA-based skin substitute. One of the numerous products added to the Anika portfolio through its acquisition of Fidia Advanced Biopolymers (now Anika Therapeutics S.r.l.), Hyalomatrix is indicated for treatment of a wide range of acute and chronic wounds.

Anika will manufacture and supply finished product to Misonix, which will be responsible for all aspects of commercialization in the United States. A recognized leader in ultrasonic wound debridement, Misonix has dedicated U.S. sales and marketing organizations in both the clinical and surgical settings where acute and chronic wounds are treated.

“This is a promising new collaboration for Anika,” said Charles H. Sherwood, Ph.D., president and chief executive officer. “Misonix will be adding Hyalomatrix to its own proprietary technologies to create a comprehensive and leading-edge protocol for wound management. Given the knowledge of U.S. sales channels for wound care products that Misonix has acquired over the years, this agreement is an important milestone in Anika’s entry into the large and growing U.S. market for advanced wound treatment.”


surf's up......crikey



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist